Long term objectives and Specific Aims To maintain high standards of care for cancer patients and to improve the quality of cancer cre in an equitable manner. To maintain a high quality data base and collect useful information about treating cancer patients. Description of the research design and methods Under the leadership of the Principal Investigator, Prof Carla I Falkson, a team of Medical Oncologists, Data Managers, Pharmacists, Nursing Personnel and other modality specialists (surgeons, radiation oncologists, etc.) Are involved in this program representing all major disciplines in cancer. The team's participation in the ECOG program is enthusiastic regarding. 1. Maintain a high accrual rate of fully evaluable patients on all ECOG therapeutic and non-therapeutic trials; 2. Maintaining an effective data management program; 3. Contributing to the ECOG's scientific and administrative program; and 4. Publishing results of ECOG studies in a timely fashion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pretoria
South Africa
Zip Code
Wolff, Antonio C; Wang, Molin; Li, Hailun et al. (2010) Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 121:111-20
Kyle, Robert A; Jacobus, Susanna; Friedenberg, William R et al. (2009) The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Cancer 115:2155-64
Flinn, Ian W; Neuberg, Donna S; Grever, Michael R et al. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-8
Messing, Edward M; Manola, Judith; Yao, Jorge et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-9
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Okuno, Scott; Ryan, Louise M; Edmonson, John H et al. (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97:1969-73
Obasaju, C; Manola, J; Hudes, G R et al. (2001) Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885. Am J Clin Oncol 24:150-4
Giantonio, B J; Hochster, H; Blum, R et al. (2001) Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 19:89-92
Leaf, A N; Wolf, B C; Kirkwood, J M et al. (2000) Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Med Oncol 17:47-51
Simpson, J F; Gray, R; Dressler, L G et al. (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059-69